Table 1 Characteristics of studies included in this review
From: Immune cell infiltration-based prognosis in prostate cancer: a review of current knowledge
References | Source of data | Study design | Sample size |
|---|---|---|---|
Xie et al. (2023) | TCGA | Case–control | 519 |
Glud et al. (2022) | Patients with Pca, Denmark; TCGA | Case–control | 181 |
Fu et al. (2021) | TCGA; GEO; Pca patients, China | Case–control | 427 |
Zhou et al. (2021) | Patients with Pca, China | Retrospective | 239 |
Ma et al. (2021) | TCGA | Retrospective | 495 |
Yang et al. (2021) | Patients with Pca, USA | Prospective | 230 |
Liu et al. (2020) | TCGA | Case–control | 550 |
Sun et al. (2020) | TCGA | Prospective | 490 |
Wu et al. (2020a) | TCGA; GEO | Case–control | 727 |
Shao et al. (2020) | TCGA; GEO; Pca patients, China | Prospective | 882 |
Zhang et al. (2019) | TCGA; GEO | Retrospective | 472 |
Watanabe et al. (2019) | Patients with Pca, Japan | Retrospective | 75 |
Meng et al. (2019) | TCGA | Case–control | 84 |
Nardone et al. (2016) | Patients with Pca, Italy | Retrospective | 22 |
Zeigler-Johnson et al. (2016) | Patients with Pca, USA | Prospective | 99 |
Davidsson et al. (2013) | Patients with Pca, Sweden | Case–control | 735 |
Nonomura et al. (2011) | Prostate cancer patients, Japan | Prospective | 71 |
Nonomura et al. (2007) | Patients with Pca, Japan | Prospective | 104 |
Andersen et al. (2021) | Patients with Pca, Denmark | Prospective | 902 |
Erlandsson et al. (2019) | Patients with PCa, Sweden | Prospective | 592 |
Yang et al. (2022) | TCGA | Case–control | 550 |
Feng et al. (2022) | TCGA | Case–control | 550 |
Zhang et al. (2022) | TCGA | Case–control | 219 |
Zhao et al. (2021) | Patients with Pca, USA; TCGA | Prospective | 605 |
Zhang et al. (2020) | TCGA | Retrospective | 487 |
Rui et al. (2019) | TCGA; GEO | Retrospective | 372 |